Näytetään tulokset 1 - 10 / 2361
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma

Vertaisarvioitu
Avoin saatavuus
DOI
10.1530/EC-21-0562
Karhapää, Hanna; Mäkelä, Siru; Lauren, Hanna; Jaakkola, Marjut; Schalin-Jäntti, Camilla; Hernberg, M...
Endocrine connections2022

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/cancers14092276
Kuusisalo, Saara; Koivunen, Jussi P.; Iivanainen, Sanna
Cancers2022

Tattoo Reactions Associated with Targeted Therapies and Immune Checkpoint Inhibitors for Advanced Cancers:A Brief Review

Avoin saatavuus
DOI
10.1159/000501590
Kluger, Nicolas
Dermatology2019

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

Vertaisarvioitu
Avoin saatavuus
DOI
10.1007/s00432-018-02835-6
Iivanainen, Sanna; Alanko, Tuomo; Peltola, Katriina; Konkola, Teemu; Ekström, Jussi; Virtanen, Henri...
Journal of cancer research and clinical oncology2019

Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1186/s12967-025-06177-z
Subbarayan, Karthikeyan; Bieber, Helena; Massa, Chiara; Rodriguez, Felipe Adonis Escalona; Hossain, ...
Journal of translational medicine2025

Effects of novel immune checkpoint inhibitors on melanoma patient’s immunesystem

Avoin saatavuus
Kasanen, Henna
Dissertationes Universitatis Helsingiensis2023

Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies

Vertaisarvioitu
Avoin saatavuus
DOI
10.1186/s12911-021-01564-0
Iivanainen, Sanna; Ekstrom, Jussi; Virtanen, Henri; Kataja, Vesa V.; Koivunen, Jussi P.
Bmc medical informatics and decision making2021

Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/ijms21020556
Iivanainen, Sanna; Koivunen, Jussi P.
International journal of molecular sciences2020

TIGIT as an emerging immune checkpoint

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/cei.13407
Harjunpää, H.; Guillerey, C.
Clinical and Experimental Immunology2020

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events

Vertaisarvioitu
Avoin saatavuus
DOI
10.1007/s00262-023-03494-4
Jokimäki, Anna; Hietala, Henna; Lemma, Jasmiini; Karhapää, Hanna; Rintala, Anna; Kaikkonen, Jari-Pek...
Cancer immunology immunotherapy2023

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma

Vertaisarvioitu
Avoin saatavuus
DOI
10.1530/EC-21-0562
2022

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/cancers14092276
2022

Tattoo Reactions Associated with Targeted Therapies and Immune Checkpoint Inhibitors for Advanced Cancers:A Brief Review

Avoin saatavuus
DOI
10.1159/000501590
2019

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

Vertaisarvioitu
Avoin saatavuus
DOI
10.1007/s00432-018-02835-6
2019

Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1186/s12967-025-06177-z
2025

Effects of novel immune checkpoint inhibitors on melanoma patient’s immunesystem

Avoin saatavuus
2023

Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies

Vertaisarvioitu
Avoin saatavuus
DOI
10.1186/s12911-021-01564-0
2021

Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/ijms21020556
2020

TIGIT as an emerging immune checkpoint

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/cei.13407
2020

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events

Vertaisarvioitu
Avoin saatavuus
DOI
10.1007/s00262-023-03494-4
2023